Clinical trials
Recurrent Renal Cell Cancer clinical trials
Below are recruiting recurrent renal cell cancer clinical trials, each written for real people, not researchers. We’re tracking 285 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07195734RecruitingPhase 2
Adding chemo or immunotherapy before surgery for advanced head and neck cancer
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
Tucson, ArizonaAges 18 years+ - NCT07645690RecruitingEarly Phase 1
CD70 CAR-T Cell Therapy for Advanced Kidney Cancer
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
BeijingAges 18–75 - NCT05768464RecruitingPhase 2
Surgery aftercare for non-clear kidney cancer at high risk
This Phase 2 trial studies an after-surgery treatment for people with non-clear types of kidney cancer who are at high risk of coming back. It aims to lower the chance of recurrence by giving extra therapy after your tumor is completely removed.
Nanjing, JiangsuAges 18–75 - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Duarte, CaliforniaAges 18 years+ - NCT06792552RecruitingPhase 1
Study of SIM0505 for advanced solid tumors
This trial tests a new drug called SIM0505 for people with advanced solid tumors that have not responded to standard treatments. The study looks at different cancer types, including ovarian cancer, kidney cancer, uterine cancer, and lung cancer, to see if SIM0505 can help shrink tumors or slow their growth.
Orlando, FloridaAges 18 years+ - NCT04754321RecruitingPhase 1
Test immunotherapy with salvage surgery and IORT for head and neck cancer
This Phase 1 trial tests a new plan that combines immunotherapy with surgery, plus a targeted radiation treatment called IORT. It is for people whose head and neck squamous cell cancer has come back or never fully went away and can be operated on. The goal is to shrink or control the cancer and see how safe the approach is.
Columbus, OhioAges 18 years+ - NCT07632365RecruitingPhase 1/Phase 2
Immunotherapy plus chemoradiation for inoperable stage III lung cancer
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
Shanghai, XuhuiAges 18 years+ - NCT06814496RecruitingPhase 1/Phase 2
Radiation and immunotherapy combo for DLL3-positive cancers
This trial combines radiation with an immunotherapy drug called tarlatamab to treat cancers that make a protein called DLL3. The goal is to see if this combination works better than either treatment alone for people with certain types of lung cancer and other tumors that have not responded to prior therapy.
Tucson, ArizonaAges 18–99 - NCT06047379RecruitingPhase 1/Phase 2
Testing NEO212 for brain tumors and metastases
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Beverly Hills, CaliforniaAges 18 years+ - NCT03786796RecruitingPhase 2
Olaparib for metastatic kidney cancer with specific DNA repair gene changes
This trial tests olaparib (a pill medicine) in people with kidney cancer that has spread and specific DNA “repair” gene mutations. The goal is to see whether this targeted treatment can slow the cancer or help it respond better after prior immunotherapy or blood-vessel–blocking therapy.
Baltimore, MarylandAges 18–120 - NCT07564232RecruitingPhase 1
LNK001 for Advanced Kidney Cancer After Prior Treatments
This Phase 1 trial tests a new cell therapy called LNK001 in patients with advanced clear-cell kidney cancer that has progressed despite prior immunotherapy and targeted drugs. The therapy is designed to recognize and attack cancer cells by targeting a protein called CAIX.
Houston, TexasAges 18–70 - NCT05024214RecruitingPhase 1/Phase 2
Test of envafolimab plus lenvatinib for advanced solid tumors
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
Bengbu, AnhuiAges 18 years+ - NCT05329532RecruitingPhase 1/Phase 2
Modi-1 cancer vaccine for several hard-to-treat cancers
This Phase 1/2 study tests a cancer vaccine called Modi-1 Moditope in people with advanced triple-negative breast cancer, head and neck cancer, ovarian/high-grade serous cancer, or kidney cancer. It aims to help the immune system better recognize and attack the cancer.
Brighton, DefaultAges 18 years+ - NCT05800587RecruitingPhase 2
Reduced-dose chemotherapy for advanced lung cancer
This trial studies a lower (reduced) dose of chemotherapy in people with advanced lung cancer who may not tolerate standard treatment. It aims to see if the treatment still works while being safer for “compromised” patients.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05874921Recruiting
Registry for adults with UTUC treated with Jelmyto
This registry collects information about adults with upper tract urothelial cancer (UTUC) who received Jelmyto after it was approved. It helps doctors understand outcomes and real-world experience with Jelmyto.
Santa Monica, CaliforniaAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06043466RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced solid tumors
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06088134Recruiting
Predicting survival after kidney cancer surgery with CT scans
This study uses a computer model to analyze your CT scans and predict how long you might stay cancer-free after surgery. It aims to help doctors personalize follow-up care for clear cell kidney cancer.
Chongqing, Chongqing MunicipalityAges Any age - NCT06265025RecruitingPhase 1/Phase 2
GM103 injection for advanced solid tumors that can't be removed
This trial tests an experimental drug called GM103 that is injected directly into tumors. It is for people with advanced solid tumors that have not responded to other treatments and cannot be surgically removed.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT06265285RecruitingPhase 2
Nivolumab at home vs. clinic for cancer treatment
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Jacksonville, FloridaAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Adelaide, South AustraliaAges 18 years+ - NCT06330038RecruitingPhase 4
Anesthesia type and lung cancer return after surgery
This study looks at whether the type of anesthesia you receive during lung cancer surgery may affect the chance of your cancer coming back. It is for people with non-small cell lung cancer who are having surgery to remove the tumor.
Seoul, Seoul-teukbyeolsiAges 19 years+
Hear when a new Recurrent Renal Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent renal cell cancer?
- Yes. Clin2 currently lists 285 recruiting recurrent renal cell cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent renal cell cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent renal cell cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.